目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 30)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 REGIONAL SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 UNITS CONSIDERED
1.6 STAKEHOLDERS
1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 35)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.2 BOTTOM-UP APPROACH: NUMBER OF TEST-BASED ANALYSES
FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: GLOBAL MARKET
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 48)
FIGURE 8 CYSTATIN C ASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 9 CYSTATIN C ASSAY INDUSTRY, BY METHOD, 2023 VS. 2028 (USD MILLION)
FIGURE 10 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 13 REGIONAL SNAPSHOT: GLOBAL MARKET

4 PREMIUM INSIGHTS (Page No. - 53)
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CYSTATIN C ASSAY MARKET
FIGURE 14 INCREASING PREVALENCE OF KIDNEY DISEASES AND GROWING GERIATRIC POPULATION TO DRIVE MARKET
4.2 NORTH AMERICA: CYSTATIN C ASSAY INDUSTRY, BY PRODUCT
FIGURE 15 KITS ACCOUNTED FOR LARGEST SHARE, BY PRODUCT, IN NORTH AMERICA
4.3 MARKET: REGIONAL MIX
FIGURE 16 ASIA PACIFIC MARKET TO WITNESS FASTEST GROWTH DURING FORECAST PERIOD
4.4 MARKET: DEVELOPED VS. EMERGING ECONOMIES
FIGURE 17 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
4.5 REGIONAL GROWTH OPPORTUNITIES IN MARKET
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 57)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 CYSTATIN C ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of kidney diseases
5.2.1.2 Growing geriatric population
TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030 VS. 2050 (MILLION)
TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2019-2050)
5.2.1.3 Recent advancements in chemiluminescence immunoassay technologies
5.2.1.4 Growth in biotechnology and biopharmaceutical industries
5.2.1.5 Increasing adoption of POC testing
TABLE 4 POC ANALYSIS DEVICES
5.2.1.6 Supportive government policies
5.2.2 RESTRAINTS
5.2.2.1 Stringent requirements for approval of cystatin C assay instruments and consumables
5.2.2.2 High development costs of cystatin C assays
TABLE 5 CYSTATIN C CONSUMABLES AND INSTRUMENTS
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Importance of companion diagnostics
TABLE 6 APPROVED AND LAUNCHED COMPANION DIAGNOSTIC ASSAYS
5.2.3.3 Development of condition-specific biomarkers and tests
5.2.4 CHALLENGES
5.2.4.1 Dearth of skilled professionals
5.3 REGULATORY OVERVIEW
5.3.1 US
FIGURE 20 US: REGULATORY PROCESS FOR IVD DEVICES
5.3.2 CANADA
FIGURE 21 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
5.3.3 EUROPE
TABLE 7 EUROPE: CLASSIFICATION OF IVD DEVICES
5.3.4 JAPAN
5.3.4.1 Japan: Regulatory process for IVD devices
TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.5 CHINA
TABLE 9 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.6 INDIA
5.3.6.1 India: Regulatory process for IVD devices
5.3.7 INDONESIA
TABLE 10 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
5.3.8 RUSSIA
TABLE 11 RUSSIA: CLASSIFICATION OF IVD DEVICES
5.3.9 SAUDI ARABIA
TABLE 12 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.10 MEXICO
5.3.10.1 Mexico: Regulatory process for IVD devices
TABLE 13 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.11 BRAZIL
5.3.11.1 Brazil: Regulatory process for IVD devices
5.3.12 SOUTH KOREA
TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.13 MIDDLE EAST
5.3.14 AFRICA
5.4 TECHNOLOGY ANALYSIS
TABLE 15 NON-GFR DETERMINANTS OF SERUM CREATININE AND CYSTATIN C
TABLE 16 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN CYSTATIN C ASSAY INDUSTRY
5.5 TRADE ANALYSIS
5.5.1 TRADE ANALYSIS FOR IMMUNOASSAYS
TABLE 17 IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2018-2022 (USD THOUSAND)
TABLE 18 EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2018-2022 (USD THOUSAND)
5.6 PATENT ANALYSIS
5.7 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 23 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.9 ECOSYSTEM ANALYSIS OF MARKET
FIGURE 24 ECOSYSTEM ANALYSIS OF MARKET
5.9.1 ROLE OF COMPANIES IN ECOSYSTEM
5.9.2 KEY PLAYERS OPERATING IN MARKET
5.10 PORTER’S FIVE FORCES ANALYSIS
TABLE 19 IMPACT OF PORTER’S FIVE FORCES ON MARKET
5.10.1 INTENSITY OF COMPETITIVE RIVALRY
5.10.2 BARGAINING POWER OF SUPPLIERS
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 THREAT OF SUBSTITUTES
5.10.5 THREAT OF NEW ENTRANTS
5.11 KEY CONFERENCES & EVENTS (2023-2024)
TABLE 20 LIST OF CONFERENCES AND EVENTS (2023-2024)
5.12 PRICING ANALYSIS
TABLE 21 CYSTATIN C ASSAY: PRICE RANGE FOR CYSTATIN C ASSAY PRODUCTS
TABLE 22 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (2022)
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
5.13.2 BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR TOP END USERS
TABLE 24 KEY BUYING CRITERIA, BY END USER
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

6 CYSTATIN C ASSAY MARKET, BY PRODUCT (Page No. - 94)
6.1 INTRODUCTION
TABLE 25 CYSTATIN C ASSAY INDUSTRY, BY PRODUCT, 2021-2028 (USD MILLION)
6.2 KITS
6.2.1 WIDE USE OF KITS IN CLINICAL LABORATORIES, HEALTHCARE SETTINGS, AND RESEARCH INSTITUTIONS TO DRIVE MARKET
TABLE 26 CYSTATIN C ASSAY KITS AVAILABLE IN MARKET
TABLE 27 CYSTATIN C ASSAY KITS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 28 CYSTATIN C ASSAY KITS MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 29 CYSTATIN C ASSAY KITS MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 30 CYSTATIN C ASSAY KITS MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)
6.2.2 REAGENTS
6.2.2.1 Wide use in diagnostic, research, and high-throughput screening to drive market
TABLE 31 CYSTATIN C ASSAY REAGENTS AVAILABLE IN MARKET
TABLE 32 CYSTATIN C REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 33 CYSTATIN C ASSAY REAGENTS MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 34 CYSTATIN C ASSAY REAGENTS MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 35 CYSTATIN C ASSAY REAGENTS MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)
6.3 ANALYZERS
6.3.1 INCREASING NUMBER OF HOSPITALS AND CLINICAL LABORATORIES TO DRIVE MARKET
TABLE 36 CYSTATIN C ASSAY ANALYZERS AVAILABLE IN MARKET
TABLE 37 CYSTATIN C ASSAY ANALYZERS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 38 CYSTATIN C ASSAY ANALYZERS MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 39 CYSTATIN C ASSAY ANALYZERS MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 40 CYSTATIN C ASSAY ANALYZERS MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)

7 CYSTATIN C ASSAY MARKET, BY METHOD (Page No. - 105)
7.1 INTRODUCTION
TABLE 41 CYSTATIN C ASSAY INDUSTRY, BY METHOD, 2021-2028 (USD MILLION)
7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY
7.2.1 WIDE ROLE IN DIAGNOSIS, PROGNOSIS, AND MONITORING OF VARIOUS RENAL DISEASES TO DRIVE MARKET
TABLE 42 ENZYME-LINKED IMMUNOSORBENT ASSAY: MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 43 ENZYME-LINKED IMMUNOSORBENT ASSAY: MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 44 ENZYME-LINKED IMMUNOSORBENT ASSAY: MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 45 ENZYME-LINKED IMMUNOSORBENT ASSAY: MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)
7.3 PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY
7.3.1 APPLICATION OF PETIA TECHNOLOGY IN ALL CLINICAL ANALYZERS TO DRIVE MARKET
TABLE 46 PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY: MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 47 PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY: MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 48 PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY: MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 49 PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY: MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)
7.4 IMMUNOFLUORESCENCE ASSAY
7.4.1 WIDE USE OF IMMUNOFLUORESCENCE ASSAY IN DIAGNOSIS OF ANTIBODIES IMMUNOLOGY AND CELL BIOLOGY RESEARCH TO DRIVE MARKET
TABLE 50 IMMUNOFLUORESCENCE ASSAY: MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 51 IMMUNOFLUORESCENCE ASSAY: MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 52 IMMUNOFLUORESCENCE ASSAY: MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 53 IMMUNOFLUORESCENCE ASSAY: MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)
7.5 CHEMILUMINESCENT IMMUNOASSAY
7.5.1 ACCESSIBILITY TO MANY CLINICAL LABORATORIES TO INCREASE DEMAND
TABLE 54 CHEMILUMINESCENT IMMUNOASSAY: MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 55 CHEMILUMINESCENT IMMUNOASSAY: MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 56 CHEMILUMINESCENT IMMUNOASSAY: MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 57 CHEMILUMINESCENT IMMUNOASSAY: MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)
7.6 PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY
7.6.1 PRECISION AND AUTOMATION CAPABILITIES IN CLINICAL LABORATORIES TO DRIVE MARKET
TABLE 58 PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY: MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 59 PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY: MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 60 PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY: MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 61 PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY: MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)
7.7 OTHER METHODS
TABLE 62 OTHER METHODS: MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 63 OTHER METHODS: MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 64 OTHER METHODS: MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 65 OTHER METHODS: MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)

8 CYSTATIN C ASSAY MARKET, BY SAMPLE TYPE (Page No. - 123)
8.1 INTRODUCTION
TABLE 66 CYSTATIN C ASSAY INDUSTRY, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
8.2 BLOOD
8.2.1 RISING PREVALENCE OF CHRONIC CONDITIONS TO DRIVE MARKET
TABLE 67 BLOOD: MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 68 BLOOD: MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 69 BLOOD: MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 70 BLOOD: MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)
8.3 URINE
8.3.1 RESEARCH APPLICATION OF URINE CYSTATIN C IN CLINICAL INVESTIGATION TO DRIVE MARKET
TABLE 71 URINE: MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 72 URINE: MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 73 URINE: MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 74 URINE: MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)

9 CYSTATIN C ASSAY MARKET, BY APPLICATION (Page No. - 130)
9.1 INTRODUCTION
TABLE 75 CYSTATIN C ASSAY INDUSTRY, BY APPLICATION, 2021-2028 (USD MILLION)
9.2 DIAGNOSTICS
9.2.1 WIDE USE OF CYSTATIN C ASSAYS IN DIAGNOSTICS TO DRIVE MARKET
TABLE 76 DIAGNOSTICS: MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 77 DIAGNOSTICS: MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 78 DIAGNOSTICS: MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 79 DIAGNOSTICS: MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)
9.3 RESEARCH
9.3.1 USE OF CYSTATIN C ASSAYS IN SCIENTIFIC STUDIES, CLINICAL TRIALS, AND BIOMARKER RESEARCH TO BOOST MARKET
TABLE 80 RESEARCH: MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 81 RESEARCH: MARKET, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 82 RESEARCH: MARKET, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 83 RESEARCH: MARKET, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)

10 CYSTATIN C ASSAY MARKET, BY END USER (Page No. - 137)
10.1 INTRODUCTION
TABLE 85 CYSTATIN C ASSAY INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
10.2 HOSPITALS
10.2.1 GROWING PATIENT POPULATION TO DRIVE MARKET
TABLE 86 MARKET FOR HOSPITALS, BY REGION, 2021-2028 (USD MILLION)
TABLE 87 MARKET FOR HOSPITALS, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 88 MARKET FOR HOSPITALS, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 89 MARKET FOR HOSPITALS, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)
10.3 CLINICAL LABORATORIES
10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO BOOST USE OF CYSTATIN C ASSAYS
TABLE 90 MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 91 MARKET FOR CLINICAL LABORATORIES, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 92 MARKET FOR CLINICAL LABORATORIES, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 93 MARKET FOR CLINICAL LABORATORIES, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, CONTRACT RESEARCH ORGANIZATIONS, AND ACADEMIC RESEARCH INSTITUTES
10.4.1 GROWING DRUG DISCOVERY AND CLINICAL STUDY AND RISING NUMBER OF COLLEGES & UNIVERSITIES TO DRIVE DEMAND
TABLE 94 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, CROS, AND ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
TABLE 95 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, CROS, AND ACADEMIC RESEARCH INSTITUTES, BY NORTH AMERICAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 96 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, CROS, AND ACADEMIC RESEARCH INSTITUTES, BY EUROPEAN COUNTRIES, 2021-2028 (USD MILLION)
TABLE 97 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, CROS, AND ACADEMIC RESEARCH INSTITUTES, BY ASIA PACIFIC COUNTRIES, 2021-2028 (USD MILLION)

11 CYSTATIN C ASSAY MARKET, BY REGION (Page No. - 147)
11.1 INTRODUCTION
TABLE 98 CYSTATIN C ASSAY INDUSTRY, BY REGION, 2021-2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 27 NORTH AMERICA: CYSTATIN C ASSAY MARKET SNAPSHOT
TABLE 99 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 100 NORTH AMERICA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 101 NORTH AMERICA: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 102 NORTH AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 103 NORTH AMERICA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 104 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.2.1 RECESSION IMPACT ON NORTH AMERICA
11.2.2 US
11.2.2.1 US to account for largest market share in North America
TABLE 105 US: KEY MACRO INDICATORS
TABLE 106 US: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 107 US: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 108 US: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 109 US: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 110 US: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Government initiatives to support market growth
TABLE 111 CANADA: KEY MACRO INDICATORS
TABLE 112 CANADA: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 113 CANADA: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 114 CANADA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 115 CANADA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 116 CANADA: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.3 EUROPE
TABLE 117 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)
11.3.1 RECESSION IMPACT ON EUROPE
TABLE 118 EUROPE: CYSTATIN C ASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 119 EUROPE: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 120 EUROPE: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 121 EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 122 EUROPE: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 123 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 High healthcare spending to drive market
TABLE 124 GERMANY: KEY MACRO INDICATORS
TABLE 125 GERMANY: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 126 GERMANY: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 127 GERMANY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 128 GERMANY: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 129 GERMANY: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Presence of favorable reimbursement policies to make market lucrative
TABLE 130 FRANCE: KEY MACRO INDICATORS
TABLE 131 FRANCE: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 132 FRANCE: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 133 FRANCE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 134 FRANCE: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 135 FRANCE: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.3.4 UK
11.3.4.1 Government support for disease diagnostics and favorable investment scenario to drive market
TABLE 136 UK: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 137 UK: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 138 UK: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 139 UK: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 140 UK: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Growing geriatric population and increasing support for research to boost market growth
TABLE 141 ITALY: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 142 ITALY: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 143 ITALY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 144 ITALY: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 145 ITALY: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Presence of well-established network of research centers, universities, and hospitals to drive market
TABLE 146 SPAIN: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 147 SPAIN: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 148 SPAIN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 149 SPAIN: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 150 SPAIN: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 151 REST OF EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2021 (% OF GDP)
TABLE 152 REST OF EUROPE: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 153 REST OF EUROPE: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 154 REST OF EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 155 REST OF EUROPE: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 156 REST OF EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.4 ASIA PACIFIC
11.4.1 RECESSION IMPACT ON ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: CYSTATIN C ASSAY MARKET SNAPSHOT
TABLE 157 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 158 ASIA PACIFIC: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 159 ASIA PACIFIC: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 160 ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 161 ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 162 ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.4.2 CHINA
11.4.2.1 High prevalence of diabetes and chronic kidney disease to drive market
TABLE 163 CHINA: KEY MACRO INDICATORS
TABLE 164 CHINA: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 165 CHINA: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 166 CHINA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 167 CHINA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 168 CHINA: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Growing medical tourism and healthcare infrastructure to drive market
TABLE 169 INDIA: KEY MACRO INDICATORS
TABLE 170 INDIA: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 171 INDIA: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 172 INDIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 173 INDIA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 174 INDIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.4.4 JAPAN
11.4.4.1 Investments in healthcare technology and research to support growth
TABLE 175 JAPAN: KEY MACRO INDICATORS
TABLE 176 JAPAN: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 177 JAPAN: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 178 JAPAN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 179 JAPAN: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 180 JAPAN: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.4.5 REST OF ASIA PACIFIC
TABLE 181 REST OF ASIA PACIFIC: DIABETES PREVALENCE (% OF POPULATION AGED 20-79), BY COUNTRY
TABLE 182 REST OF ASIA PACIFIC: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 183 REST OF ASIA PACIFIC: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 184 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 185 REST OF ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 186 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
11.5 REST OF THE WORLD
TABLE 187 REST OF THE WORLD: POPULATION AGED 65 AND ABOVE (% OF TOTAL POPULATION)
11.5.1 RECESSION IMPACT ON REST OF THE WORLD
TABLE 188 REST OF THE WORLD: CYSTATIN C ASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 189 REST OF THE WORLD: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 190 REST OF THE WORLD: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 191 REST OF THE WORLD: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 192 REST OF THE WORLD: MARKET, BY END USER, 2021-2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 210)
12.1 OVERVIEW
12.2 STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 193 OVERVIEW OF STRATEGIES ADOPTED BY KEY CYSTATIN C ASSAY MARKET PLAYERS
12.3 MARKET RANKING ANALYSIS, 2022
FIGURE 29 CYSTATIN C ASSAY INDUSTRY RANKING ANALYSIS, 2022
12.4 REVENUE SHARE ANALYSIS, 2022
FIGURE 30 REVENUE ANALYSIS OF TOP FOUR PUBLIC MARKET PLAYERS
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 PERVASIVE PLAYERS
12.5.3 PARTICIPANTS
12.5.4 EMERGING LEADERS
FIGURE 31 CYSTATIN C ASSAY INDUSTRY: COMPANY EVALUATION MATRIX (2022)
12.6 SMES/STARTUPS EVALUATION MATRIX
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 32 CYSTATIN C ASSAY INDUSTRY: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
12.7 COMPETITIVE BENCHMARKING
12.7.1 COMPANY FOOTPRINT ANALYSIS
TABLE 194 COMPANY FOOTPRINT ANALYSIS
TABLE 195 COMPANY PRODUCT FOOTPRINT
TABLE 196 COMPANY REGIONAL FOOTPRINT
TABLE 197 CYSTATIN C ASSAY MARKET: DETAILED LIST OF KEY SMES/STARTUPS
12.8 COMPETITIVE SCENARIO
12.8.1 PRODUCT LAUNCHES AND APPROVALS
TABLE 198 PRODUCT LAUNCHES AND APPROVALS, 2022
12.8.2 DEALS
TABLE 199 DEALS, 2021

13 COMPANY PROFILES (Page No. - 222)
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 ROCHE DIAGNOSTICS LIMITED
TABLE 200 ROCHE DIAGNOSTICS LIMITED: BUSINESS OVERVIEW
FIGURE 33 ROCHE DIAGNOSTICS LIMITED.: COMPANY SNAPSHOT
13.1.2 ABBOTT
TABLE 201 ABBOTT: BUSINESS OVERVIEW
FIGURE 34 ABBOTT: COMPANY SNAPSHOT
13.1.3 THERMO FISHER SCIENTIFIC INC.
TABLE 202 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
13.1.4 SIEMENS HEALTHCARE GMBH
TABLE 203 SIEMENS HEALTHCARE GMBH: BUSINESS OVERVIEW
FIGURE 36 SIEMENS HEALTHCARE GMBH: COMPANY SNAPSHOT
13.1.5 BIO-TECHNE
TABLE 204 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 37 BIO-TECHNE: COMPANY SNAPSHOT
13.1.6 AGILENT TECHNOLOGIES, INC.
TABLE 205 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 38 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
13.1.7 GENTIAN DIAGNOSTICS ASA
TABLE 206 GENTIAN DIAGNOSTICS ASA: BUSINESS OVERVIEW
FIGURE 39 GENTIAN DIAGNOSTICS ASA: COMPANY SNAPSHOT
13.1.8 ABCAM PLC
TABLE 207 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 40 ABCAM PLC.: COMPANY SNAPSHOT
13.1.9 GETEIN BIOTECH, INC.
TABLE 208 GETEIN BIOTECH, INC.: BUSINESS OVERVIEW
FIGURE 41 GETEIN BIOTECH, INC.: COMPANY SNAPSHOT
13.1.10 SINO BIOLOGICAL, INC.
TABLE 209 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW
FIGURE 42 SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT
13.1.11 EUROLYSER DIAGNOSTICA GMBH
TABLE 210 EUROLYSER DIAGNOSTICA GMBH: BUSINESS OVERVIEW
13.1.12 DIAZYME LABORATORIES, INC
TABLE 211 DIAZYME LABORATORIES, INC.: BUSINESS OVERVIEW
13.1.13 KAMIYA BIOMEDICAL COMPANY
TABLE 212 KAMIYA BIOMEDICAL COMPANY: BUSINESS OVERVIEW
13.1.14 RANDOX LABORATORIES LTD.
TABLE 213 RANDOX LABORATORIES LTD..: BUSINESS OVERVIEW
13.1.15 DIASYS DIAGNOSTIC SYSTEMS GMBH
TABLE 214 DIASYS DIAGNOSTIC SYSTEMS GMBH: BUSINESS OVERVIEW
13.1.16 CEPHAM LIFE SCIENCES
TABLE 215 CEPHAM LIFE SCIENCES: BUSINESS OVERVIEW
13.2 OTHER PLAYERS
13.2.1 ETHOS BIOSCIENCES
13.2.2 IMMUNODIAGNOSTICS LIMITED
13.2.3 SEKISUI DIAGNOSTICS
13.2.4 AALTO SCIENTIFIC, LTD.
13.2.5 RAYBIOTECH LIFE, INC.
13.2.6 ARBOR ASSAYS
13.2.7 CUSABIO TECHNOLOGY LLC
13.2.8 PROTEINTECH GROUP, INC.
13.2.9 ZHEJIANG KANGTE BIOTECHNOLOGY CO., LTD.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX (Page No. - 261)
14.1 INSIGHTS FROM INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 CUSTOMIZATION OPTIONS
14.5 RELATED REPORTS
14.6 AUTHOR DETAILS